News

Discover Why Medical Cannabis Has Healthcare Companies Scrambling to Invest in the $10 Billion-dollar Opportunity

Shared Content
Written by Shared Content
Frost & Sullivan will host an interactive briefing discussing  the medical cannabis market revenue trends and challenges

SANTA CLARA, Calif. (October 18, 2018) – Frost & Sullivan, the growth partnership company, announced today that it will host a live, complimentary Growth Innovation Leadership (GIL) briefing titled, “Medical Marijuana Market Trends – Future Clinical Role of Medical Marijuana & CBD,” on Tuesday, October 30, 2018, from 1:00 to 2:00 PM Pacific Time. The webinar will offer expert insight from Nitin Naik, Global Vice President, Life Sciences, Barbara Gilmore, Senior Consultant, Life Sciences, both at Frost & Sullivan, and Dr. Joseph C. Maroon, Clinical Professor and Vice Chairman, at the University of Pittsburgh.

 For more information and to register for the webinar, please visit http://frost.ly/2t3.

“The use of medical [cannabis] is sparking keen interest not only with investors, but also doctors and patients. All but four states in the US have legalized either medical [cannabis] or CBD use.  There are over 770 clinical trials underway studying the use of medical cannabis in various diseases and another more than 500 trials studying the use of CBD,” noted Gilmore. “With all of these studies underway, it is interesting to note that states that have legalized [cannabis] for recreational use have seen a steady decrease in the number of recorded patient prescriptions.  This is a trend that will be studied going forward as physicians learn more about the medical [cannabis] efficacy as it related to the diseases it is successfully treating.”Medical cannabis use is driving industry revenues into the billions. Investments by pharmaceutical and Big Tobacco companies in the development of cannabis and CBD-based products and devices, along with healthcare-conscious consumers having access to these products, are spurring growth. Physicians, aware of increasingly widespread medical [cannabis] legalization, are interested in understanding the potential of these treatments. In the US states where cannabis is approved, the use of prescription drugs, including the use of opioids, has decreased.

The informative webinar will cover key insights:

  • Learn about a variety of medical cannabis science and clinical uses/applications (patient experiences);
    • Discover health-related applications of medical cannabis based on interactions with the endocannabinoid system; and
    • Explore the latest clinical research in cancer, neurological, psychological, metabolic and pain disorders using medical cannabis.

The event will also be recorded and available for on-demand viewing at http://frost.ly/1ti

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Contact us: Start the discussion.

For more information, visit ww2.frost.com or call +1 (877) 463-7678.

FOR IMMEDIATE RELEASE

Press Contact:

Mariana Fernandez

Frost & Sullivan

+1 (210) 348.1012

mariana.fernandez@frost.com

About the author

Shared Content

Shared Content

Leave a Comment